Pri Bamford

X-Lab has been around since 2006 and was born out of the desire to solve one of the digitally-focussed challenges diagnostic organisations face when providing care to patients. This means creating unique solutions which enable diagnostic healthcare organisations to work together in the most efficient, safe, and cost effective ways possible. Our core product, Labgnostic, is a service which connects almost 200 diagnostic organisations (primarily pathology labs) together through exchange hubs across Europe and the US. Labgnostic - which has historically been marketed under NPEx (the National Pathology Exchange) in the UK - is the market leader in the UK and, was the data infrastructure for the UK’s national COVID-19 testing response which saw the service process more than 300 million COVID-19 results for UK citizens. While we’ve been operating in the UK for over 17 years, X-Lab has the appetite for growth, opportunities, and scalability of a start-up. As we continue to grow, we’re looking to expand through both the diversity of our product offering and with our geographic reach of our already multinational service to global markets, notably in the US and Australia. X-Lab’s new product, called LabReach, is in development in the UK. LabReach acts as an order communications portal to enable end users, from any organisation or location, to more easily order tests and receive results from any lab. Ultimately, our vision is to be the leader in connecting the world's diagnostic systems to improve healthcare for all.